On 25 February, Japanese pharmaceutical giant Takeda announced the inauguration of its new office in Biopolis. The expanded space will host key Takeda functions – its Emerging Markets Business Unit headquarters (which was previously based in Zurich), Takeda Development Centre Asia and Vaccine Business Unit. The move is part of Takeda’s business strategy to consolidate and streamline its operations in Singapore.
Takeda has maintained a presence in Asia-Pacific for more than 50 years, and entered Singapore in 2008. It has over 1,700 employees in 10 countries and expansion in Asia is a core component of Takeda’s long-term growth strategies. As a result of its new office in Biopolis, Takeda will increase its total headcount here to about 200, with more than 50 new hires.
The company is eyeing five emerging-market areas - the Asia-Pacific, Greater China, Latin America, the Near East, Middle East and Africa (NEMEA) and the Commonwealth of independent states - and expects to grow its emerging-markets business by 10 per cent. Takeda said its five emerging market areas will account for 70 per cent of the total projected pharmaceutical growth between 2013 and 2017.
To date, eight of the top 10 Japanese pharmaceutical companies, including Takeda, have established regional headquarters here.